Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Philip B. Reitano who wrote (2894)	12/1/1997 8:09:00 AM
From: Linda Kaplan	Respond to of 23519

Headline: Vivus Announces U.K. Approval of MUSE -- alprostadil ====================================================================== MENLO PARK, Calif.--(BW HealthWire)--Dec. 1, 1997--VIVUS, Inc. (NASDAQ:VVUS) today announced that MUSE(R) (alprostadil), the Company's treatment for erectile dysfunction, has received authorization from the Medicines Control Agency to market MUSE in the United Kingdom. Astra Pharmaceuticals Ltd. based in Kings Langley, England, will market the product in the U.K. under a distribution agreement between Astra AB of Sweden and VIVUS International. "We are proud to have Astra as our marketing and distribution partner for the U.K.," stated Leland Wilson, President and Chief Executive Officer of VIVUS. "Initial acceptance of MUSE in the United States has been very strong, allowing the product to become the leader in the U.S. erectile dysfunction market during its first nine months on the market." Terry Nida, Vice President, Europe, will facilitate the activities of the Company in Europe from a subsidiary, VIVUS, U.K. Ltd., which is headquartered in Windsor, U.K. MUSE (alprostadil), a treatment for erectile dysfunction, is a pre-filled, single-use plastic applicator containing the drug alprostadil, a medication that increases penile blood flow. MUSE, launched in the U.S. in January 1997, had U.S. product sales of over $100 million in the first nine months of 1997. "Astra U.K. will soon launch MUSE in the U.K. as the lead market in the European Union (EU). We anticipate registration of the product in most of the EU countries during 1998," said an Astra spokesperson. The U.K. approval triggers a $2 million milestone payment to VIVUS from Astra under the terms of an agreement with Astra signed in May 1996. Astra will market and distribute MUSE in Europe, Australia and New Zealand as well as the South and Central American countries, once individual country approvals are obtained. Founded in 1991, VIVUS, Inc. is a leader in the development of advanced therapeutic systems for the treatment of erectile dysfunction. VIVUS has pioneered a novel therapy for erectile dysfunction known as the transurethral system for erection. This therapy consists of a proprietary, non-invasive, drug delivery system that delivers pharmacologic agents via the urethra. Note to editors and investors: MUSE is a registered trademark of VIVUS Inc. Additional written materials, recent releases and Company information are available through a variety of sources, including: the VIVUS home page (www.vivus.com) and the VIVUS Fax-On-Demand Service (1-888-329-5719). CONTACT: VIVUS, Inc. Nina W. Ferrari, 415/325-5511 (Director, IR) David Yntema, 415/325-5511 (CFO) IR@VIVUS.com KEYWORD: CALIFORNIA INDUSTRY KEYWORD: MEDICINE PHARMACEUTICAL PRODUCT Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com Copyright 1997, Business Wire

To: Philip B. Reitano who wrote (2894)	12/1/1997 8:12:00 AM
From: Zebra 365	Read Replies (1) \| Respond to of 23519

VVUS RECEIVES UK APPROVAL !! biz.yahoo.com Vivus Announces U.K. Approval of MUSE -- alprostadil MENLO PARK, Calif.--(BW HealthWire)--Dec. 1, 1997--VIVUS, Inc. (NASDAQ:VVUS - news) today announced that MUSE(R) (alprostadil), the Company's treatment for erectile dysfunction, has received authorization from the Medicines Control Agency to market MUSE in the United Kingdom. Astra Pharmaceuticals Ltd. based in Kings Langley, England, will market the product in the U.K. under a distribution agreement between Astra AB of Sweden and VIVUS International. ''We are proud to have Astra as our marketing and distribution partner for the U.K.,'' stated Leland Wilson, President and Chief Executive Officer of VIVUS. ''Initial acceptance of MUSE in the United States has been very strong, allowing the product to become the leader in the U.S. erectile dysfunction market during its first nine months on the market.'' Terry Nida, Vice President, Europe, will facilitate the activities of the Company in Europe from a subsidiary, VIVUS, U.K. Ltd., which is headquartered in Windsor, U.K. MUSE (alprostadil), a treatment for erectile dysfunction, is a pre-filled, single-use plastic applicator containing the drug alprostadil, a medication that increases penile blood flow. MUSE, launched in the U.S. in January 1997, had U.S. product sales of over $100 million in the first nine months of 1997. ''Astra U.K. will soon launch MUSE in the U.K. as the lead market in the European Union (EU). We anticipate registration of the product in most of the EU countries during 1998,'' said an Astra spokesperson. The U.K. approval triggers a $2 million milestone payment to VIVUS from Astra under the terms of an agreement with Astra signed in May 1996. Astra will market and distribute MUSE in Europe, Australia and New Zealand as well as the South and Central American countries, once individual country approvals are obtained. Founded in 1991, VIVUS, Inc. is a leader in the development of advanced therapeutic systems for the treatment of erectile dysfunction. VIVUS has pioneered a novel therapy for erectile dysfunction known as the transurethral system for erection. This therapy consists of a proprietary, non-invasive, drug delivery system that delivers pharmacologic agents via the urethra. Note to editors and investors: MUSE is a registered trademark of VIVUS Inc. Additional written materials, recent releases and Company information are available through a variety of sources, including: the VIVUS home page (www.vivus.com) and the VIVUS Fax-On-Demand Service (1-888-329-5719). ---------------------------------------------------------------------- Contact: VIVUS, Inc. Nina W. Ferrari, 415/325-5511 (Director, IR) David Yntema, 415/325-5511 (CFO) IR@VIVUS.com ----------------------------------------------------------------------